Heidy King-Jones insider trades: Spyre Therapeutics (SYRE) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Heidy reports to the SEC
Open-market buys and sales
2 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Oct 1, 2026 | SYRE | ↓ Sell | 28,933 | $91.03 | $2.6M | Direct | Oct 2, 2026 (1d) |
| Sep 2, 2026 | SYRE | ↓ Sell | 28,399 | $87.35 | $2.5M | Direct | Sep 3, 2026 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other SYRE insiders
Open-market trades in the last 12 months
About Heidy King-Jones's insider trades
Heidy King-Jones is See Remarks at Spyre Therapeutics (SYRE). Since Sep 2, 2026, Heidy has reported no open-market purchases and 2 sales worth $5.1M on SEC Form 4. In the last 12 months: 2 sales ($5.1M).
Their filings also include grants and awards (12 filings), option exercises (2 filings), shares returned to the company (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every SYRE insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.